The Top 5 Biosimilar Articles for the Week of January 31

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of January 31, 2022.

Number 5: Two new studies investigated Imraldi (SB5), an adalimumab biosimilar developed by Samsung Bioepis, in inflammatory bowel disease (IBD).

Number 4: The Biosimilars Forum has appointed Cofounder and President Juliana (Julie) M. Reed, as the new executive director. Reed shared some of her goals for the Biosimilars Forum in an interview with The Center for Biosimilars®.

Number 3: After increasing its ownership stake in Samsung Bioepis from 15% to 50% in 2018, Biogen is now selling it for up to $2.3 billion.

Number 2: Three studies from the Indian Institute of Technology in Delhi laid out the biosimilar approval guidelines and market growth projections for several countries in the Asia Pacific region, Latin America, the Middle East and Africa.

Number 1: US biosimilar uptake faces several barriers, including misconceptions regarding biosimilar efficacy and a misalignment of prescription incentives between payers, providers, and patients, panelists discussed.

To read all of these articles and more, visit centerforbiosimilars.com.